Systematic Review: T-Cell–based Assays for the Diagnosis of Latent Tuberculosis Infection: An Update

1. 

   View larger version:

   • In this window
   • In a new window

   Figure 1. Forest plot of studies estimating sensitivity of interferon-γ–release assays in patients with active tuberculosis as a surrogate for latent tuberculous infection.

   Point estimates for sensitivity and 95% CIs are shown along with pooled estimates. Top. QuantiFERON-TB Gold (16 studies). Middle. QuantiFERON-TB Gold In-Tube (6 studies). Bottom. T-SPOT.TB (13 studies).
2. 

   View larger version:

   • In this window
   • In a new window

   Figure 2. Forest plot of studies estimating specificity of interferon-γ–release assays in populations at very low risk for latent tuberculous infection.

   Point estimates for specificity and 95% CIs are shown along with pooled estimates. Top. QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube (braille Calmette–Guérin [BCG] nonvaccinated; 8 studies). Middle. QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube (BCG vaccinated; 8 studies). Bottom. T-SPOT.TB (predominantly BCG vaccinated; 6 studies).
3. 

   View larger version:

   • In this window
   • In a new window

   Figure 3. Forest plot of studies estimating sensitivity and specificity of the tuberculin skin test.

   Point estimates for sensitivity and specificity and 95% CIs are shown along with pooled estimates. Top. Sensitivity (20 studies). Middle. Specificity in non–bacille Calmette–Guérin-vaccinated populations (6 studies). Bottom. Specificity in bacille Calmette–Guérin-vaccinated populations (6 studies).